Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2017; 9(02): 132-135
DOI: 10.4103/0974-2727.199639
Original Article

Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia infections

Priyam Batra
Department of Microbiology, All Institute of Medical Sciences, New Delhi, India
,
Purva Mathur
Department of Microbiology, All Institute of Medical Sciences, New Delhi, India
,
Mahesh C. Misra
Department of Surgery, All Institute of Medical Sciences, New Delhi, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

INTRODUCTION: Stenotrophomonas maltophilia earlier had limited pathogenic potential, but now with growing degree of immunosuppression in general population, it is being recognized as an important nosocomial pathogen.

METHODOLOGY: A retrospective 7 years study was carried out to determine the clinical characteristics of all patients with Stenotrophomonas infections, antibiotic resistance pattern, and risk factors associated with hospital mortality. All patients with Stenotrophomonas culture positivity were identified and their medical records were reviewed. Risk factor associated with hospital mortality was analyzed.

RESULTS: A total of 123 samples obtained from 88 patients were culture positive. Most patients presented with bacteremia (45, 51%) followed by pneumonia (37, 42%) and skin and soft tissue infections (6, 7%). About 23 of 88 Stenotrophomonas infected patients had co-infection. Percentage resistance to cotrimoxazole; 8 (5.4%) was lower than that for levofloxacin; 18 (12%). Twenty-eight patients died during hospital stay. Intensive Care Unit admission (P = 0.0002), mechanical ventilation (P = 0.0004), central venous catheterization (P = 0.0227), urethral catheterization (P = 0.0484), and previous antibiotic intake (P = 0.0026) were independent risk factors associated with mortality.

CONCLUSION: Our findings suggest that Stenotrophomonas can cause various infections irrespective of patient’s immune status and irrespective of potential source. Thus, Stenotrophomonas should be thought of as potential pathogen and its isolation should be looked with clinical suspicion.

Keywords

Epidemiology - risk factors - Stenotrophomonas


Publication History

Received: 29 June 2016

Accepted: 23 August 2016

Article published online:
19 February 2020

© 2017.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Low CY, Rotstein C. Emerging fungal infections in immunocompromised patients. F1000 Rep 2011;3:14.
  • 2 Wu H, Wang JT, Shiau YR, Wang HY, Lauderdale TL, Chang SC; TSAR Hospitals. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. J Microbiol Immunol Infect 2012;45:120-6.
  • 3 Xun M, Zhang Y, Li BL, Wu M, Zong Y, Yin YM. Clinical characteristics and risk factors of infections caused by Stenotrophomonas maltophilia in a hospital in Northwest China. J Infect Dev Ctries 2014;8:1000-5.
  • 4 Naeem T, Absar M, Somily AM. Antibiotic resistance among clinical isolates of Stenotrophomonas maltophilia at a teaching hospital in Riyadh, Saudi Arabia. J Ayub Med Coll Abbottabad 2012;24:30-3.
  • 5 Chhablani J, Sudhalkar A, Jindal A, Das T, Motukupally SR, Sharma S, et al. Stenotrophomonas maltophilia endogenous endophthalmitis: Clinical presentation, antibiotic susceptibility, and outcomes. Clin Ophthalmol 2014;8:1523-6.
  • 6 Chawla K, Vishwanath S, Munim FC. Nonfermenting Gram-negative bacilli other than Pseudomonas aeruginosa and Acinetobacter spp. Causing respiratory tract infections in a tertiary care center. J Glob Infect Dis 2013;5:144-8.
  • 7 Brooke JS. Stenotrophomonas maltophilia: An emerging global opportunistic pathogen. Clin Microbiol Rev 2012;25:2-41.
  • 8 Thomas J, Prabhu VN, Varaprasad IR, Agrawal S, Narsimulu G. Stenotrophomonas maltophilia: A very rare cause of tropical pyomyositis. Int J Rheum Dis 2010;13:89-90.
  • 9 Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128-40.
  • 10 Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-32.
  • 11 Lipuma JJ, Curie BJ, Peacock SJ, Vandamme PAR. Burkholderia, Stenotrophomonas, Ralstonia, Cupriavidus, Pandoraea, Brevundimonas, Comamonas, Delftia, and Acidovorax. In: Baron EJ, Pfaller MA, Jorgensen JH, Yolken RH, editors. Mannual of Clinical Microbiology. 8th ed. Washington, DC: ASM Press; 2010. p. 692-71.
  • 12 Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty Third Informational Supplement CLSI Document M100-S23. Vol. 33. Wayne, PA: Clinical Laboratory Standards Institute; 2013.
  • 13 Winn WC, Allen SD, Allen S, Janda WM, Koneman EW, Schreckenberger PC. et al. Koneman's Color Atlas and Textbook of Diagnostic Microbiology. 6th ed. United States of America: Lippincott Williams and Wilkins; 2006.
  • 14 Naidu P, Smith S. A review of 11 years of Stenotrophomonas maltophilia blood isolates at a tertiary care institute in Canada. Can J Infect Dis Med Microbiol 2012;23:165-9.
  • 15 Lai CH, Chi CY, Chen HP, Chen TL, Lai CJ, Fung CP, et al. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect 2004;37:350-8.
  • 16 Wang CH, Lin JC, Lin HA, Chang FY, Wang NC, Chiu SK, et al. Comparisons between patients with trimethoprim-sulfamethoxazole-susceptible and trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia monomicrobial bacteremia: A 10-year retrospective study. J Microbiol Immunol Infect 2016;49:378-86.
  • 17 Fouhy Y, Scanlon K, Schouest K, Spillane C, Crossman L, Avison MB, et al. Diffusible signal factor-dependent cell-cell signaling and virulence in the nosocomial pathogen Stenotrophomonas maltophilia. J Bacteriol 2007;189:4964-8.